Abstract Therapy-related myelodysplastic syndrome (t-MDS) is a serious complication of chemoradiotherapy for primary diseases. This cohort was aimed to determine the clinical features and outcomes of t-MDS in comparison with de novo MDS. I retrieved data of 666 cases with t-MDS, and 29,703 cases with de novo MDS diagnosed between 2001 and 2012 from the database of U.S. National Cancer Institute. Survival curves were estimated, and Cox proportional hazards model was constructed. Compared with patients with de novo MDS, patients with t-MDS tended to be young (median age; 65 vs. 76 years, p \ 0.001), and were more likely to be female-sex (51.4 vs. 44.7%, p = 0.001). Median overall survival (OS) and 5-year OS rate are significantly poorer in t-MDS than de novo MDS (17.2 months and 22% vs. 31 months and 32%, respectively, p \ .001). In t-MDS cases, with a median follow-up of 16 months (range 1-143 months), 521 cases (78.2%) had died. Of which, 78 (15%) cases had died from acute myeloid leukemia, and 66 (12.7%) cases had died from solid cancers. Of the total 66 cases died from solid cancers; 19 cases (28.8%) died from cancer of lung/ bronchus, 11 cases (16.7%) breast cancers, and 10 cases (15.2%) ovarian cancer. In a multivariate analysis adjusted for clinical features, calendar period and radiotherapy, the hazard of mortality was significantly low in de novo MDS compared with t-MDS (hazard ratio 0.59; p \ .001). In conclusions, t-MDS is a distinct entity of MDS in terms of clinical characteristics and prognosis.
Introduction
Therapy-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) is a serious complication of cytotoxic chemotherapy and/or radiation for a neoplastic or non-neoplastic diseases [1] . The incidence of t-MDS/ AML following conventional therapy ranges from 0.8 to 6.3% at 20 years, and 1.1 to 24.3% at 5 years after autologous hematopoietic stem cell transplantation (HSCT) [2] . The classic form of t-MDS/AML follows treatment with alkylating agents and/or radiotherapy with latency period of 5-7 years. It is characterized by abnormalities of chromosomes 5 or 7 and preceded by a myelodysplastic phase. Less common form of t-MDS/AML occurring after exposure to topoisomerase II inhibitors with a short latency period (2-3 years), and it is characterized by balanced translocations involving 11q23 or 21q22 [1] . The most common primary cancers in t-MDS/AML are lymphomas and breast cancer, as these cancers are associated with prolonged survival [3, 4] . Patients with t-MDS/AML had unfavourable cytogenetics with a dismal prognosis (median survival was less than 1 year) [3, 4] . Five year survival of t-MDS/AML after allogeneic HSCT of 22% [5] . The patient age, cytogenetics, and complete remission at the time of transplantation are prognostic factors for survival of t-MDS/AML after allogeneic HSCT [6] .
This population-based cohort highlights, the clinical features, and survival outcomes of t-MDS in comparison with de novo MDS. To the best of my knowledge, it is the largest population-review of t-MDS to date.
Patients and Methods
SEER stands for Surveillance, Epidemiology, and End Results that currently collects and publishes cancer incidence and survival data from 18 population-based cancer registries covering approximately 28% of the US population. From 18 SEER registries [7] Clinical and demographic features of patients were expressed as proportions (%) and frequencies (n) for categorical variables, or as median and range for continuous variables. Associations between categorical variables were analyzed using v2 analysis.
The overall survival (OS) was defined as the interval between the date of diagnosis to the date of death or date of last follow-up, and data were censored at December 31, 2012 from the date of MDS diagnosis. Survival curves were generated using Kaplan-Meier method and compared by log-rank test. Multivariate analysis was performed applying the Cox regression. All calculated p values are two sided, and p \ .05 was considered statistically significant. 
de novo MDS. The clinical and the survival outcomes of these cases are given in a Table 1 . In t-MDS cases, approximately two-third (60.8%) of the patients were younger than 70 years at the time of diagnosis, compared to approximately one third (31.3%) of patients with de novo MDS (p \ 0.001). The median age of patients with t-MDS at presentation was 65 years (range 2-97 year), that was low compared with 76 years (range 1-106 year) for patients with de novo MDS (p \ 0.001).
Women were more frequently affected than men in t-MDS, compared with patients with de novo MDS (51.4 vs. 44.7%, p = 0.001) ( Table 1 ). In a large series, t-MDS/ AML is more frequent in females, because of the high frequency of t-MDS/AML after treatment of breast cancer [3, 4] . Smith et al. [3] reviewed 306 patients with t-MDS/t-AML treated at the University of Chicago; 32 patients (10%) have a history of breast cancers, and 19 patients (6.2%) with a history of ovary/uterus cancers. In a single institute study between 1980 and 2003, Rund et al. [4] reviewed 96 Jewish cases with t-MDS/AML, 30% of cases had a history of breast and ovarian cancers. In addition to chemoradiotherapy, granulocyte colony-stimulating factors are doubling the risk of t-MDS/AML in females with a breast cancers [10] . I found that, Asian race was more common in de novo MDS than t-MDS (6.5 vs. 3.9%, p = 0.048). Patients with t-MDS were more likely than de novo MDS to receive radiotherapy (3.2 vs. 0.7%, p \ 0.001) ( Table 1) .
At presentation, 505 of 666 cases (75.8%) with t-MDS had a history of antecedent cancer, and 161 cases (24.2%) without antecedent cancer. The SEER database did not capture data regarding types of antecedent cancer. Noticeable, up to 22% of t-MDS/AML cases have a history of chemoradiotheray for non-neoplastic diseases [11] . Furthermore, around 5% of t-MDS/AML was associated with autoimmune disorders [3, 12] .
Causes of Death (COD)
In the overall patients (n = 30,369), with a median followup of 21 months (range 1-143 months), 19,632 (64.6%) patients died at last follow-up. Of these, 2296 cases (11.7%) died from AML and 775 cases (3.9%) died from solid cancers. One report pointed out that, AML accounted for 15% of deceased cases in a lower-Risk MDS [13] . Naqvi et al. [14] retrospectively analyzed 600 consecutive patients with MDS who presented to MD Anderson Cancer Center between 2002-2004; of these, 456 patients (76.0%) died and 123 patients (20.5%) evolved into AML.
In t-MDS cases, with a median follow-up of 16 months (range 1-143 months), 521 cases (78.2%) died; of which, 78 (15%) cases died from AML and 66 (12.7%) cases died from solid cancers ( Table 1) . In one report, 30% of t-AML No number of cases, NOS not otherwise specified had a prior history of t-MDS [5] . Of the total 66 cases died from solid cancers in t-MDS cases; 19 cases (28.8%) died from cancer of lung/bronchus, 11 cases (16.7%) breast cancers, and 10 cases (15.2) ovarian cancer ( Table 2) . Solid cancer-related deaths were significantly more frequent in t-MDS compared to de novo MDS (12.7 vs. 3.7%, p \ 0.001). Median age of deceased t-MDS cases was low compared to deceased de novo MDS (66 vs. 78 years, p \ 0.001) [data not shown].
Survival and Prognosis
Regarding subtypes of de novo MDS, the poor survival had observed in refractory anemia with excess blasts in transformation (9.9 months), and refractory anemia with excess blasts (13.6 months) ( Table 3) . In univariate analysis, median OS and 5-year OS of patients with t-MDS were significantly inferior compared to those with de novo MDS (17.2 months and 22% vs. 31.1 months and 32%, respectively, p \ 0.001) ( Table 1, Fig. 2) . A two series pointed out that the median OS of t-MDS/AML was 8 to 10 months [3, 4] . In the current study, the 5-year OS was 22% (95% CI 19-25) that was very close to 22% (95% CI 19-29) of 323 t-AML cases received allergenic transplants [5] . In the Chicago series (n = 306), the median OS after diagnosis of t-MDS/AML was 8 months and 5-years OS was less than 10% [3] . In a multivariate analysis adjusted for demographics, calendar period and radiotherapy; patients with de novo MDS had better overall survival [adjusted hazard ratio (aHR) 0.59; 95% confidence interval (CI) 0.54-0.64, p \ 0.001] than patients with t-MDS (Table 4 ; Fig. 2 ). Previous multivariate analyses showed that t-MDS/AML are unfavourable prognostic factors, independent of unfavorable cytogenetics [11, 12, 15] . Poor outcome of t-MDS/AML is related to persistence of the primary malignant disease, chronic immunosuppression from prior disease or on-going therapy, organ and bone marrow injury from prior therapy [1, 16] . In addition, t-MDS/AML patients had a high frequency of unfavourable cytogenetics compared to de novo MDS/AML [4, 17] .
In this work, median survival times after the diagnosis of t-MDS by age group were 17.9 months for \70 years age group, 15 months for 70-79 age group, and 19.4 months for C80 years age group (p = 0.013). Moreover, patients aged \70 years had a favorable survival compared those aged C70 years (17.9 vs. 16 months, p = 0.013) (Fig. 3) . It seems that the poor survival observed in the t-AML patients aged greater than or equal to 70 years old (16 months), was related to the poorest survival in age group 70-79 years old (15 months).
In the entire cohort, the risk of all-cause mortality in 70-79 years age group and C80 years age groups are 1.46-fold and 2.1-fold higher than those reported in \70 years age group (p \ 0.001) ( Table 4 ). Poor prognosis of old age is attributed to unfavourable cytogenetics, multidrug resistance, and co-morbidities [18] . Several reports showed that age is a risk factor for mortality in t-MDSL/AML after autologous HSCT [5, 19] . In addition, age is one of parameters of prognostic scoring system for den novo MDS [20] , and t-MDS [21] . In the current work, women have a long median survival compared to men (35.44 vs. 27.2 months, p \ 0.001), and risk of all cause-mortality in women is 22% lower than men (aHR 0.78; 95% CI 0.76-0.80, p \ 0.001) ( Table 4 ). In a retrospective study of 1157 patients with primary MDS diagnosed by the German and Austrian MDS study group, age and gender had a prognostic role [22] . In general, I observed that femalesex is a lucky variable outcome in several blood cancers [23, 24] . Finally, unmarried patients (p \ 0.001) and the recent years of diagnosis (p = 0.035) are unfavourable prognostic factors (Table 4) .
This SEER analysis had limitations, such as, lack of information regarding types of primary cancers, prior therapy, and cytogenetics. However, our cohort is a population-based that provides a valuable data regarding clinical prognostic factors, and survival outcomes.
In conclusion, t-MDS is different from de novo MDS in terms of clinical features and outcomes. 
